- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02803138
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C (CITRINE)
September 18, 2019 updated by: AbbVie
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C - An Observational Study in Israel (CITRINE STUDY)
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions.
This observational study was the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to local label, under real world conditions in Israel in a clinical practice patient population.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This was a prospective, multi-center observational study in participants receiving the interferon-free ABBVIE REGIMEN ± RBV in Israel.
The prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the participant the opportunity to participate in this study.
Adults chronically infected with HCV, receiving the interferon-free ABBVIE REGIMEN, were offered the opportunity to participate in this study during a routine clinical visit at the participating sites.
Follow-up visits, treatment, procedures, and diagnostic methods followed physicians' routine clinical practice.
Data were collected at the following time windows: baseline, early on-treatment visit, mid-treatment visit (for participants with a treatment duration of 24 weeks), end of treatment (EoT), early post-treatment and 12 and 24 weeks after the end of treatment (representing sustained virologic response 12 weeks after the end of treatment [SVR12] and sustained virologic response 24 weeks after the end of treatment [SVR24]).
Study Type
Observational
Enrollment (Actual)
256
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Afula, Israel, 18341
- Ha'Emek Medical Center /ID# 153695
-
Be'er Sheva, Israel, 84101
- Soroka Medical Ctr /ID# 153697
-
Be'er Ya'akov, Israel, 70300
- Assaf Harofeh Medical Center /ID# 153708
-
Gush Dan, Israel, 7565016
- Maccabi Health Services /ID# 158647
-
Hadera, Israel, 38100
- Hillel Yaffe Medical Center /ID# 153702
-
Haifa, Israel, 3109601
- Rambam Health Care Campus /ID# 153694
-
Haifa, Israel, 3339419
- Bnai Zion Medical Center /ID# 153700
-
Haifa, Israel, 3436212
- The Lady Davis Carmel MC /ID# 153692
-
Holon, Israel, 58100
- The Edith Wolfson Medical Cent /ID# 153706
-
Jerusalem, Israel, 91031
- Shaare Zedek Medical Center /ID# 153699
-
Jerusalem, Israel, 91120
- Hadassah /ID# 153701
-
Kfar Saba, Israel, 44281
- Meir Medical Center /ID# 153698
-
Nahariya, Israel, 22100
- Western Galilee Medical Center /ID# 153705
-
Ramat Gan, Israel, 5262100
- Sheba Medical Center /ID# 153707
-
-
HaDarom
-
Be'er Sheva, HaDarom, Israel, 84101
- Soroka Medical Center /ID# 169357
-
-
Tel-Aviv
-
Petakh Tikva, Tel-Aviv, Israel, 4941492
- Rabin Medical Center /ID# 153696
-
Petakh Tikva, Tel-Aviv, Israel, 4941492
- Rabin Medical Center /ID# 158648
-
Tel Aviv-Yafo, Tel-Aviv, Israel, 6423906
- Tel Aviv Sourasky Medical Ctr /ID# 153693
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Participants with chronic hepatitis C virus infection, genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± ribavirin.
Description
- Treatment-naïve or -experienced adult male or female participants with confirmed chronic hepatitis C (CHC), genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) according to standard of care and in line with the current local label
- If RBV was co-administered with the ABBVIE REGIMEN, it had to be prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy)
- Participants had to voluntarily sign and date an informed consent form prior to inclusion into the study
- Participants must not have participated or intended to participate in a concurrent interventional therapeutic trial
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with HCV genotype 1 or 4
Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablets; 1000 or 1200 mg divided twice a day) up to 24 weeks
|
Co-formulated tablet
Other Names:
Tablet
Other Names:
Tablet
Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
Time Frame: 12 weeks after the last actual dose of study drug
|
SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than 50 IU/mL 12 weeks after the last actual dose of study drug.
|
12 weeks after the last actual dose of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Viral Breakthrough
Time Frame: Up to 24 weeks
|
Viral breakthrough was defined as at least 1 documented hepatitis C virus ribonucleic acid (HCV RNA) level less than 50 IU/mL followed by HCV RNA level greater than or equal to 50 IU/mL during treatment.
|
Up to 24 weeks
|
Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria
Time Frame: 12 weeks after the last actual dose of study drug
|
The number of participants with missing SVR12 data or SVR12 nonresponder participants who did not meet criteria for on-treatment virologic failure, relapse, premature treatment discontinuation, and who did not have an Insufficient virological response reported was documented.
|
12 weeks after the last actual dose of study drug
|
Percentage of Participants With Virologic Response at End of Treatment (EoT)
Time Frame: Up to 24 weeks
|
Virologic response was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than 50 IU/mL at the end of treatment.
|
Up to 24 weeks
|
Percentage of Participants With Relapse
Time Frame: Up to 48 weeks after the last actual dose of study drug
|
Relapse was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than 50 IU/mL at the end of treatment followed by HCV RNA level greater than or equal to 50 IU/mL.
|
Up to 48 weeks after the last actual dose of study drug
|
Percentage of Participants With On-treatment Virologic Failure
Time Frame: 12 weeks after the last actual dose of study drug
|
On-treatment virologic failure was defined as breakthrough (at least 1 documented hepatitis C virus ribonucleic acid (HCV RNA) less than 50 IU/mL followed by HCV RNA greater than or equal to 50 IU/mL during treatment) or failure to suppress (each measured on-treatment HCV RNA value greater than or equal to 50 IU/mL).
|
12 weeks after the last actual dose of study drug
|
Percentage of Participants Meeting Relapse Criteria
Time Frame: 12 weeks after the last actual dose of study drug
|
Relapse was defined as hepatitis C virus ribonucleic acid (HCV RNA) less than 50 IU/mL at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA greater than or equal to 50 IU/mL post-treatment.
|
12 weeks after the last actual dose of study drug
|
Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria
Time Frame: 12 weeks after the last actual dose of study drug
|
Premature study drug discontinuation was defined as participants who prematurely discontinued study drug with no on-treatment virologic failure.
|
12 weeks after the last actual dose of study drug
|
Percentage of Participants With Sufficient Follow-up Who Achieved Sustained Virological Response 12 Weeks Posttreatment
Time Frame: 12 weeks (at least 70 days) after the last actual dose of study drug
|
Sustained virologic response was defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than 50 IU/mL 12 weeks after the last dose of study drug. The core population with sufficient follow-up data 12 weeks after the last actual dose of study drug (CPSFU12) was defined as all participants who fulfilled one of the following criteria:
|
12 weeks (at least 70 days) after the last actual dose of study drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 7, 2016
Primary Completion (Actual)
October 21, 2018
Study Completion (Actual)
October 21, 2018
Study Registration Dates
First Submitted
June 14, 2016
First Submitted That Met QC Criteria
June 14, 2016
First Posted (Estimate)
June 16, 2016
Study Record Updates
Last Update Posted (Actual)
October 11, 2019
Last Update Submitted That Met QC Criteria
September 18, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis, Chronic
- Hepatitis C, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ribavirin
- Ritonavir
Other Study ID Numbers
- P16-014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hospices Civils de LyonCompleted
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis cChina
-
Ascletis Pharmaceuticals Co., Ltd.CompletedChronic Hepatitis cChina
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on Ombitasvir/paritaprevir/ritonavir
-
AbbVieTerminated
-
AbbVieCompletedChronic Hepatitis C InfectionUnited States, Belgium, Germany, Puerto Rico, Spain
-
AbbVieCompletedChronic Hepatitis C Infection
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVieCompletedCompensated Cirrhosis | Chronic Hepatitis C Infection
-
AbbVieCompletedDecompensated Cirrhosis | Chronic Hepatitis C | Hepatitis C Virus